Protox Therapeutics Inc. (TSX-V: PRX)
announced today that preclinical data demonstrating PRX302's validity as a
treatment for prostate cancer and benign prostatic hyperplasia (BPH) is being
presented in a poster session at the 97th Meeting of the American Association
of Cancer Research (AACR), which is being held this week at the Washington
Convention Centre in Washington, D.C.
